Based on NIH | Can endometrial cancer cause vision problems at night, and what mechanisms or treatment side effects might explain this symptom?

Night vision problems in someone with endometrial cancer are possible, but they are uncommon and usually have explanations other than direct tumor growth in the eye. In many cases, night‑time vision difficulty (nyctalopia) may stem from rare immune‑related effects of the cancer, unusual metastatic spread to the eye, or side effects from therapies such as chemotherapy or immunotherapy. Recognizing the mechanism matters because some causes are reversible if treated early.

How endometrial cancer itself could affect vision

• Paraneoplastic retinopathy (cancer‑associated retinopathy, CAR): Very rarely, endometrial cancer can trigger an autoimmune reaction where the body makes antibodies that attack the retina, leading to reduced rod and cone function and symptoms such as worsening night vision, glare sensitivity, photopsias (flashes), and progressive vision loss. This has been reported in endometrial cancer, with antiretinal antibodies and characteristic electroretinogram (ERG) changes. Early treatment of the underlying tumor and immunosuppression may help, although outcomes vary. ^{[1] [2] [3]}
• Paraneoplastic optic neuropathy: Another rare immune‑mediated phenomenon can affect the optic nerve, causing visual decline; management often involves steroids, IVIG, or plasma exchange alongside cancer treatment. ^[4]
• Ocular metastasis: Metastasis from endometrial cancer to ocular structures is uncommon, but isolated cases exist (for example, to the iris), which can disturb vision, cause pain, or blur. Prompt ophthalmic evaluation is needed if suspected. ^[5]

Treatment‑related causes of night vision difficulty

Cancer therapies for endometrial cancer especially combinations that include chemotherapy and immune checkpoint inhibitors can produce eye and vision side effects ranging from dry eye and light sensitivity to uveitis and retinal or optic nerve problems. Some of these issues can alter low‑light vision and may improve if found early and managed.

• Paclitaxel: Has been linked to vision disorders including cystoid macular edema (CME), which reduces visual acuity and can impair contrast sensitivity and night vision; stopping the drug may lead to improvement. ^{[6] [7]}
• Carboplatin: Visual disturbances are uncommon at standard doses, but high doses have been associated with vision loss that sometimes improves after discontinuation. ^{[8] [9]}
• Dostarlimab (Jemperli): As an immune checkpoint inhibitor (anti‑PD‑1), it can cause immune‑mediated eye inflammation such as keratitis and uveitis, which may present with blurred vision, light sensitivity, and potential night‑time difficulties; evaluation and steroids are often needed. ^{[10] [11]}
• Durvalumab (anti‑PD‑L1): Immune‑related ocular toxicities reported include dry eye, uveitis/iritis, episcleritis, blepharitis, and optic neuritis, any of which can degrade dim‑light vision or cause glare and photophobia; early recognition and management are recommended. ^{[12] [13] [14]}
• Immunotherapy‑associated retinopathy: Cases have been described in endometrial cancer where checkpoint inhibitor combinations produced a retinopathy mimicking CAR, presenting with nyctalopia and improving after stopping the drugs. ^[15]

Other medical contributors that can worsen night vision

• Endocrine effects from immunotherapy: These drugs can cause thyroiditis, hypothyroidism, or adrenal insufficiency; hormonal imbalances can lead to fatigue, visual complaints, and ocular surface disease, indirectly worsening vision quality in low light. ^{[10] [16]}
• Anemia and general health: Cancer and its treatments can cause anemia, which may not directly damage the eye but can lower retinal oxygenation and contribute to visual fatigue, glare, and perceived dim‑light difficulties in some people. (General physiological mechanism; monitor with clinicians.)
• Dry eye and surface inflammation: Dry eye is common with immunotherapy and can reduce contrast sensitivity and worsen night driving; lubricating drops and anti‑inflammatory therapy can help. ^{[12] [13] [14]}

Red‑flag symptoms that need urgent eye care

• Sudden or rapidly worsening vision loss, eye pain, new floaters or flashes, severe light sensitivity, or a curtain‑like shadow in vision warrant immediate evaluation. Immune‑mediated eye inflammation (uveitis, optic neuritis) needs prompt treatment to protect vision. ^{[12] [13]}

---

What evaluation typically includes

• Comprehensive eye exam with dilated fundus evaluation to look for inflammation, macular edema, optic nerve changes, or signs of metastasis. (Standard of care.)
• Specialized testing when indicated: optical coherence tomography (OCT) for macular changes; ERG if paraneoplastic retinopathy is suspected; visual fields; and, rarely, serologic testing for antiretinal antibodies. ^{[1] [2] [4]}
• Oncology review of medications and timing of symptoms to assess for drug causality; labs to screen for endocrine adverse events if on immunotherapy. ^{[10] [16] [12]}

---

Management approaches

• Drug‑related ocular toxicity: Depending on severity, strategies may include artificial tears, topical or systemic steroids, and sometimes pausing or discontinuing the responsible therapy; CME related to paclitaxel may improve after stopping the drug. ^{[6] [7]}
• Immune‑mediated inflammation (uveitis/optic neuritis): Prompt ophthalmology‑guided steroids and coordination with oncology about immunotherapy dosing are standard; severe cases may need additional immunosuppression. ^{[12] [13]}
• Suspected paraneoplastic retinopathy: Treating the underlying cancer plus immunomodulatory therapies (steroids, IVIG, plasmapheresis) may help; outcomes vary and early intervention is ideal. ^{[4] [2]}
• Ocular metastasis: Local ocular treatments (e.g., radiation, surgery) alongside systemic cancer therapy may be considered, tailored to location and extent. ^[5]

---

Quick reference: mechanisms and links to night vision

Mechanism	How it affects night vision	Typical signs	Notes
Paraneoplastic retinopathy (CAR)	Rod and cone dysfunction → nyctalopia, glare	Photopsias, ring scotomas, reduced/flat ERG	Reported in endometrial cancer; antibody‑mediated. [1] [2] [3] [4]
Ocular metastasis	Distorts ocular structures	Blurred vision, possible pain or visible lesions	Rare iris metastasis reported. [5]
Paclitaxel toxicity	Cystoid macular edema	Blurry/“waxy” vision, poor contrast	May improve after cessation. [6] [7]
Carboplatin toxicity	Rare visual disturbances (dose‑related)	Transient vision loss at high doses	Uncommon at standard dosing. [8] [9]
Dostarlimab immune effects	Keratitis/uveitis	Pain, photophobia, blur	Needs prompt anti‑inflammatory care. [10] [11]
Durvalumab immune effects	Dry eye, uveitis/optic neuritis	Dryness, light sensitivity, blur	Early recognition prevents damage. [12] [13] [14]

---

Key takeaways

• Night vision problems in endometrial cancer are not typical, but they can occur due to rare paraneoplastic syndromes, unusual metastasis, or more commonly as side effects of chemotherapy and immunotherapy. Immune‑related eye inflammation (like uveitis) and paclitaxel‑related macular edema are important and potentially reversible causes if treated early. ^{[6] [7] [10] [11] [12] [13]}
• Because some mechanisms threaten permanent vision loss, new or worsening night‑time vision issues during or after cancer treatment should be evaluated promptly by an ophthalmologist, with coordination between eye care and oncology teams for medication adjustments and targeted therapy. Early diagnosis and management can preserve vision and allow safer continuation of cancer care. ^{[12] [13] [4]}